


What is claimed is:

1. A compound of Formula (I):



- 5 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is independently phenyl substituted with 0-3 R^6 or pyridinyl substituted with 0-3 R^6 ;

R^2 is, at each occurrence, independently halogen or C_{1-4} alkyl;

- 10 R^3 is independently selected from: CF_3 , 4-halo-Ph, 4-CN-Ph, 4- $CO_2(C_{1-2}$ alkyl)-Ph, 2-halo-4-CN-Ph, and pyrimidin-2-yl;


R^4 is independently C_{1-4} alkyl or cyclopropylmethyl;

R^5 is, at each occurrence, independently halogen; and

R^6 , at each occurrence, is independently selected from: OH, halogen, CN, C_{1-4} alkyl, and C_{1-4} alkoxy.

15

2. A compound according to claim 1, wherein the compound is of Formula (II):



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

- 20 3. A compound according to claim 1 or claim 2, wherein:

R¹ is independently phenyl substituted with 0-3 R⁶ or pyridinyl substituted with 0-2 R⁶;


R² is independently halogen or C₁₋₄ alkyl;

R³ is independently selected from: CF₃, 4-halo-Ph, 4-CN-Ph,
5 4-CO₂(C₁₋₂ alkyl)-Ph, 2-halo-4-CN-Ph, and pyrimidin-2-yl;

R⁴ is independently C₁₋₄ alkyl or cyclopropylmethyl; and

R⁶, at each occurrence, is independently selected from: halogen, CN, C₁₋₄ alkyl,
and C₁₋₄ alkoxy.

10 4. A compound according to any one of claims 1 to 3, wherein the compound is of Formula (III):



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

15 5. A compound according to any one of claims 1 to 4, wherein:

R² is independently halogen or C₁₋₄ alkyl;

R⁴ is independently C₁₋₄ alkyl; and

R⁶, at each occurrence, is independently selected from: halogen, CN, C₁₋₄ alkyl,
and C₁₋₄ alkoxy.

20

6. A compound according to any one of claims 1 to 5, wherein:





R² is independently C₁₋₄ alkyl;

and






R⁶, at each occurrence, is independently selected from: halogen, C₁₋₄ alkyl, and

25 C₁₋₄ alkoxy.


7. A compound according to any one of claims 1 to 6, wherein:
R² is methyl;
R⁴ is methyl; and
5 R⁶, at each occurrence, is independently selected from: Cl and methoxy.
8. A compound according to claim 1, wherein the compound is selected from:









WO 2014/078610








5







5



5




, and








or a stereoisomer, or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 1, wherein the compound is selected from:



5







or a stereoisomer, or a pharmaceutically acceptable salt thereof.

5

10. A compound according to claim 1, wherein the compound is selected from:





5

or a stereoisomer, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier
and a compound of any one of claims 1 to 10, or a stereoisomer, a tautomer, or a
10 pharmaceutically acceptable salt thereof.

12. The use of the pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical composition further comprising one or more other additional therapeutic agents including: anti-diabetic agents, anti-hyperglycemic agents,
5 anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic
10 agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, and anti-inflammatory agents.


13. The pharmaceutical composition according to claim 11, further comprising a dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.
15

14. The use of a compound of any one of claims 1 to 10 in the manufacture of a medicament for the prevention, modulation or treatment of diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury,
20 cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein, high low-density lipoprotein, non-cardiac ischemia, pancreatitis, lipid
25 disorders, neurodegenerative disease, cognitive impairment, dementia, liver diseases and liver cirrhosis.

15. A compound for use according to claim 14, wherein the compound of any one of claims 1 to 10 is used simultaneously, separately or sequentially with an additional
30 therapeutic agent.

What is claimed is:

1. A compound of Formula (I):



- 5 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R¹ is independently phenyl substituted with 0-3 R⁶ or pyridinyl substituted with 0-3 R⁶;

R² is, at each occurrence, independently halogen or C₁₋₄ alkyl;

R³ is independently selected from: CF₃, 4-halo-Ph, 4-CN-Ph,

- 10 4-CO₂(C₁₋₂ alkyl)-Ph, 2-halo-4-CN-Ph, and pyrimidin-2-yl;


R⁴ is independently C₁₋₄ alkyl or cyclopropylmethyl;

R⁵ is, at each occurrence, independently halogen; and

R⁶, at each occurrence, is independently selected from: OH, halogen, CN, C₁₋₄ alkyl, and C₁₋₄ alkoxy.

15

2. A compound according to claim 1, wherein the compound is of Formula (II):



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

- 20 3. A compound according to claim 1 or claim 2, wherein:

R^1 is independently phenyl substituted with 0-3 R^6 or pyridinyl substituted with 0-2 R^6 ;

R^2 is independently halogen or C_{1-4} alkyl;


R^3 is independently selected from: CF_3 , 4-halo-Ph, 4-CN-Ph,

5 4- $CO_2(C_{1-2}$ alkyl)-Ph, 2-halo-4-CN-Ph, and pyrimidin-2-yl;

R^4 is independently C_{1-4} alkyl or cyclopropylmethyl; and

R^6 , at each occurrence, is independently selected from: halogen, CN, C_{1-4} alkyl, and C_{1-4} alkoxy.

10 4. A compound according to any one of claims 1 to 3, wherein the compound is of Formula (III):



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

15 5. A compound according to any one of claims 1 to 4, wherein:

R^2 is independently halogen or C_{1-4} alkyl;

R^4 is independently C_{1-4} alkyl; and

R^6 , at each occurrence, is independently selected from: halogen, CN, C_{1-4} alkyl, and C_{1-4} alkoxy.

20

6. A compound according to any one of claims 1 to 5, wherein:

R^2 is independently C_{1-4} alkyl;

and

R^6 , at each occurrence, is independently selected from: halogen, C_{1-4} alkyl, and

25 C_{1-4} alkoxy.





7. A compound according to any one of claims 1 to 6, wherein:

R^2 is methyl;







R^4 is methyl; and

5 R^6 , at each occurrence, is independently selected from: Cl and methoxy.







8. A compound according to claim 1, wherein the compound is selected from:






10




5




5



5




, and









or a stereoisomer, or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 1, wherein the compound is selected from:



5












or a stereoisomer, or a pharmaceutically acceptable salt thereof.

5

10. A compound according to claim 1, wherein the compound is selected from:





5

or a stereoisomer, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 10, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

10

12. The use of the pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical composition further comprising one or more other additional therapeutic agents including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, and anti-inflammatory agents.

13. The pharmaceutical composition according to claim 11, further comprising a dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.

14. The use of a compound of any one of claims 1 to 10 in the manufacture of a medicament for the prevention, modulation or treatment of diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein, high low-density lipoprotein, non-cardiac ischemia, pancreatitis, lipid disorders, neurodegenerative disease, cognitive impairment, dementia, liver diseases and liver cirrhosis.

15. The use according to claim 14, wherein the compound of any one of claims 1 to 10 is used simultaneously, separately or sequentially with an additional therapeutic agent.